Immunoprophylactic strategies against respiratory influenza virus infection

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2227-2232

  Saravolac, Edward G ^a,d   Sabuda, Deana ^b   Crist, Colin ^c   Blasetti, Karen ^a   Schnell, Glen ^a   Yang, Huiming ^e   Kende, Meir ^f   Levy, Hilton B ^g   Wong, Jonathan P ^a  

^a Defence Rsch Establishment Suffield   (Canada)

^b Department of Surgery   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d JOHNSON AND JOHNSON   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^g Ribopharm Inc   (United States)

Author keywords

Immunoprophylaxis; Influenza A; Liposome

Indexed keywords

CARBOXYMETHYLCELLULOSE; DOUBLE STRANDED RNA; GAMMA INTERFERON; LIPOSOME; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFLUENZA VACCINATION; INFLUENZA VIRUS A; LONG TERM CARE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SURVIVAL RATE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA, HUMAN; INTERFERON-GAMMA, RECOMBINANT; LIPOSOMES; MICE; POLY I-C; TIME FACTORS;

EID: 0035925552     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00450-3     Document Type: Conference Paper

References (40)

1. Prevention and control of influenza: Recommendations of the immunization practices advisory committee
2. Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance
3. Neuraminidase inhibitors for treatment of influenza A and B infections
4. Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from lungs of infected animals treated with defective interfering virus
5. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies
6. Intranasal interferon α-2b for seasonal prophylaxis of respiratory infection
7. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients
8. Vaccine adjuvant effects, and immune response, to synthetic polymners MVE and poly (ICLC)
9. Clinical toxicity of interferons in cancer patients: A review
10. Preliminary trial of poly (I,C)-LC in multiple sclerosis
11. Liposomes as pharmaceuticals
12. Liposome-mediated treatment of viral, bacterial and protazoal infections
13. Clearance of phosphatidyl choline and cholesterol from liposomes, liposomes loaded with metaproterenol and rabbit surfactant from adult rabbit lungs
14. Enhanced protection against respiratory influenza A infection mice by liposome-encapsulated antibody
15. Hemagglutination and hemagglutination inhibition tests
16. The nature of viruses
17. A simple procedure for preparing liposomes capable of high efficiency under mild conditions
18. Interferons
19. Comparative therapeutic efficacy of recombinant interferons -α, -β, and -γ against alphatogavirus, bunyavirus, flavivirus and herpesvirus infections
20. The determination of an immunologically active dose of interferon-gamma in patients with melanoma
21. Antimicrobial and imunopathologic effects of cytokine-induced nitric oxide synthesis
22. Inhibition of viral replication by interferon-γ-induced nitric oxide synthase
23. A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer
24. Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ
25. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production
26. The application of liposomes to antiviral therapy: Passive immunity and immunomodulation
27. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley virus infection in mice
28. A modified polyriboinosinic-polyribocyticylic acid complex that induces interferon in monkeys
29. Immunomodulation of natural killer activity by polyribonucleotides
30. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta)
31. Prophylactic and therapeutic efficacy of poly (I,C)-LC against Rift Valley fever virus infection in mice
32. Successful prophylaxis against rabies in mice and rhesus monkeys: The interferon system and vaccine
33. Protection and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys
34. Prophylactic and therapeutic efficacies of Poly (IC.LC) against respiratory influenza A virus infection in mice
35. An ECOG phase I-II pilot study of poly-ICLC in patients with metastatic malignant melanoma
36. Phase I-II trials of poly-ICLC in malignant brain tumor patients
37. Treatment of advanced ovarian cancer with poly-ICLC
38. Liposome-mediated immunotherapy against respiratory influenza virus infection using double stranded RNA poly ICLC
39. The immune response to influenza infection